METHENAMINE HIPPURATE | N017681 | ESJAY PHARMA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Pharmobedient Consulting, LLC FDA-2025-P-3709 Pharmobedient Consulting, LLC filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Methenamine Hippurate Tablets 500 mg suitable for submission in an Abbreviated New Drug Application, with the Reference Listed Drug bei | Suitability | 2025-09-11 | Open | Pharmobedient Consulting |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.